Total
0
Shares
Argenica Therapeutics (ASX:AGN)- CEO, Dr Liz Dallimore (left) and COO,Dr Samantha South (right)
CEO, Dr Liz Dallimore (left) and COO,Dr Samantha South (right)
Source: Argenica/ Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Newly listed biotech Argenica Therapeutics (AGN) confirms two of its manufacturing partners have successfully scaled-up the manufacturing of ARG-007
  • ARG-007 is the company’s lead drug and aims to reduce brain tissue death after a stroke
  • Argenica’s Australian based peptide manufacturer, AusPep, has tested the drug production, which saw achieved a purity profile of 99.9 per cent, well above the required level for clinical trial
  • The company also engaged US-based GMP peptide manufacturer, AmbioPharm, to conduct similar trials on ARG-007
  • On the market this afternoon, Argenica is up 2.94 per cent and is trading at 35 cents per share

Argenica Therapeutics (AGN) has confirmed two of its manufacturing partners have successfully scaled-up the manufacturing of ARG-007.

ARG-007 is the company’s lead drug and aims to reduce brain tissue death after a stroke.

Notably, the manufacturing of the drug will be up to the good manufacturing practice (GMP) standards.

GMP is a globally-recognised standard for ensuring rigorous and continually monitored processes in drug manufacturing to minimise risks and ensure drugs are safe and effective when administered to patients.

Argenica’s Australian based peptide manufacturer, AusPep, has tested all aspects of ARG-007 production and confirmed the successful process development and scale up of GMP grade ARG-007.

The scaled up GMP grade achieved a purity profile of 99.9 per cent, well above
the required level for clinical trial.

Achieving GMP manufacturing of ARG-007 was needed for Argenica to
undertake safety and toxicology studies in pre-clinical experiments before commencing its inhuman phase one clinical trials.

The company also engaged US-based GMP peptide manufacturer, AmbioPharm, to conduct similar trials on ARG-007, who also achieved process development optimisation of the manufacturing of ARG-007 at a purity of 99.3 per cent.

Commenting on the manufacturing milestone was Chief Executive Officer Liz Dallimore.

“Passing the GMP scale up manufacturing milestone and process optimisation is incredibly exciting for Argenica, especially at the very high peptide purities generated,” Dr Dallimore said.

“We have de-risked our reliance on a sole manufacturing partner and achieved high purity product from both manufacturers. We now have a high purity GMP grade product that we will use in both our pre-clinical studies and phase one clinical trial.”

On the market this afternoon, Argenica was up 2.94 per cent and is trading at 35 cents per share at 3:30 pm AEST.

 

AGN by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.